Levetiracetam reverses synaptic deficits produced by overexpression of sV2A

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Nowack, Amy ^a   Malarkey, Erik B ^a   Yao, Jia ^a   Bleckert, Adam ^b   Hill, Jessica ^a   Bajjalieh, Sandra M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; ETIRACETAM; MEMBRANE PROTEIN; SYNAPTIC VESICLE PROTEIN 2A; SYNAPTIC VESICLE PROTEIN 2A BINDING PROTEIN; SYNAPTOTAGMIN; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DRUG DERIVATIVE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; NERVE PROTEIN; PIRACETAM; SV2A PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; KNOCKOUT MOUSE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN TRANSPORT; SEIZURE; SYNAPSE; SYNAPTIC DEFICIT; SYNAPTIC TRANSMISSION; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG EFFECT; METABOLISM; MOUSE MUTANT; NERVE CELL; RAT; SECRETION; SYNAPTOSOME;

MUS;

ANIMALS; GREEN FLUORESCENT PROTEINS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; NEUROTRANSMITTER AGENTS; PHENOTYPE; PIRACETAM; PRESYNAPTIC TERMINALS; PROTEIN TRANSPORT; RATS; RECOMBINANT FUSION PROTEINS; SYNAPSES; SYNAPTOTAGMINS;

EID: 84855268762     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029560     Document Type: Article

References (53)

1. De Smedt T, Raedt R, Vonck K, Boon P, (2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13: 57-78.
2. Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, et al. (2007) Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 68: 1010-1013.
3. Kinrys G, Wygant LE, Pardo TB, Melo M, (2006) Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 67: 211-214.
4. Zhang W, Connor KM, Davidson JR, (2005) Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19: 551-553.
5. Enggaard TP, Klitgaard NA, Sindrup SH, (2006) Specific effect of levetiracetam in experimental human pain models. Eur J Pain 10: 193-198.
6. Dunteman ED, (2005) Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 19: 35-43.
7. Price MJ, (2004) Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20: 33-36.
8. Bushara KO, Malik T, Exconde RE, (2005) The effect of levetiracetam on essential tremor. Neurology 64: 1078-1080.
9. McGavin CL, John V, Musser WS, (2003) Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 61: 419.
10. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C, (2008) Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69: 546-554.
11. Zivkovic SA, Costa G, Bond G, Abu-Elmagd KM, (2008) Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol Scand 117: 351-353.
12. Striano P, Elefante A, Coppola A, Tortora F, Zara F, et al. (2007) Dramatic response to levetiracetam in post-ischaemic Holmes' tremor. J Neurol Neurosurg Psychiatry 78: 438-439.
13. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101: 9861-9866.
14. Buckley K, Kelly RB, (1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. Journal of Cell Biology 100: 1284-1294.
15. Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, et al. (2009) Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 50: 1729-1740.
16. Bajjalieh SM, Peterson K, Linial M, Scheller RH, (1993) Brain contains two forms of synaptic vesicle protein 2. Prodeedings of the National Academy of Sciences, USA 90: 2150-2154.
17. Bajjalieh SM, Peterson K, Shinghal R, Scheller RH, (1992) SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257: 1271-1273.
18. Feany MB, Lee S, Edwards RH, Buckley KM, (1992) The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 70: 861-867.
19. Janz R, Hofmann K, Sudhof TC, (1998) SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. Journal of Neuroscience 15: 9269-9281.
20. Bajjalieh SM, Franz G, Weimann JM, McConnell SK, Scheller RH, (1994) Differential expression of Synaptic Vesicle Protein 2 (SV2) isoforms. The Journal of Neuroscience 14: 5223-5235.
21. Gronborg M, Pavlos NJ, Brunk I, Chua JJ, Munster-Wandowski A, et al. (2010) Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J Neurosci 30: 2-12.
22. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang H-Z, et al. (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Science, USA 96: 115268-115273.
23. Janz R, Goda Y, Geppert M, Missler M, Sudhof TC, (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24: 1003-1016.
24. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM, (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26: 1303-1313.
25. Wan Q-F, Zhou Z-Y, Thakur P, Vila A, Sherry DM, et al. (2010) SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66: 884-895.
26. Chang WP, Sudhof TC, (2009) SV2 renders primed synaptic vesicles competent for Ca2+-induced exocytosis. J Neurosci 29: 883-897.
27. Xu T, Bajjalieh SM, (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nature Cell Biology 3: 691-698.
28. Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM, (2010) Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci 30: 5569-5578.
29. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT, (2007) Asymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm. Epilepsy Res 73: 266-274.
30. Matveeva EA, Whiteheart SW, Slevin JT, (2003) Accumulation of 7S SNARE complexes in hippocampal synaptosomes from chronically kindled rats. J Neurochem 84: 621-624.
31. Ohno Y, Ishihara S, Terada R, Kikuta M, Sofue N, et al. (2009) Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Biochem Biophys Res Commun 390: 415-420.
32. Winden KD, Karsten SL, Bragin A, Kudo LC, Gehman L, et al. (2011) A systems level, functional genomics analysis of chronic epilepsy. PLoS One 6: e20763.
33. Cohen JE, Lee PR, Chen S, Li W, Fields RD, (2011) MicroRNA regulation of homeostatic synaptic plasticity. Proc Natl Acad Sci U S A 108: 11650-11655.
34. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT, (2008) Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia 49: 1749-1758.
35. Yang XF, Weisenfeld A, Rothman SM, (2007) Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission. Epilepsia 48: 1861-1869.
36. Meehan AL, Yang X, McAdams BD, Yuan L, Rothman SM, (2011) A New Mechanism for Antiepileptic Drug Action: Vesicular Entry May Mediate the Effects of Levetiracetam. J Neurophysiol 106: 1227-1239.
37. Nowack A, Yao J, Custer KL, Bajjalieh SM, (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol 299: C960-967.
38. Dobrunz LE, Stevens CF, (1997) Heterogeneity of release probability, facilitation, and depletion at central synapses. Neuron 18: 995-1008.
39. De Smedt T, Raedt R, Vonck K, Boon P, (2007) Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev 13: 43-56.
40. Yang XF, Rothman SM, (2009) Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission. Seizure 18: 615-619.
41. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C, (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22: 207-213.
42. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E, (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286: 137-146.
43. Lazzell DR, Belizaire R, Thakur P, Sherry DM, Janz R, (2004) SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem 279: 52124-52131.
44. Morgans CW, Kensel-Hammes P, Hurley JB, Burton K, Idzerda R, et al. (2009) Loss of the Synaptic Vesicle Protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS ONE 4: e5230.
45. Mutch SA, Kensel-Hammes P, Gadd JC, Fujimoto BS, Allen RW, et al. (2011) Protein quantification at the single vesicle level reveals that a subset of synaptic vesicle proteins are trafficked with high precision. J Neurosci 31: 1461-1470.
46. Abderrahmani A, Niederhauser G, Plaisance V, Roehrich ME, Lenain V, et al. (2004) Complexin I regulates glucose-induced secretion in pancreatic beta-cells. J Cell Sci 117: 2239-2247.
47. Huttner WB, Schiebler P, Greengard P, DeCammilli P, (1983) Synapsin I (protein I), a nerve terminal-specific phosphoportein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. Journal of Cell Biology 96: 1373-1388.
48. Itakura M, Misawa H, Sekiguchi M, Takahashi S, Takahashi M, (1999) Transfection analysis of functional roles of complexin I and II in the exocytosis of two different types of secretory vesicles. Biochem Biophys Res Commun 265: 691-696.
49. Liu J, Guo T, Wu J, Bai X, Zhou Q, et al. (2007) Overexpression of complexin in PC12 cells inhibits exocytosis by preventing SNARE complex recycling. Biochemistry (Mosc) 72: 439-444.
50. Xue M, Reim K, Chen X, Chao HT, Deng H, et al. (2007) Distinct domains of complexin I differentially regulate neurotransmitter release. Nat Struct Mol Biol 14: 949-958.
51. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA, (2008) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 50: 422-433.
52. Schivell AE, Batchelor RH, Bajjalieh SM, (1996) Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. Journal of Biological Chemistry 271: 27770-27775.
53. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, et al. (2001) Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 12: 1103-1108.